Onward 2025: Stock Lift-Up

1.513 Posts
Pagina: 1 2 3 4 5 6 ... 76 »» | Laatste | Omlaag ↓
  1. forum rang 5 K. Wiebes 1 januari 2025 11:55
    www.nature.com/articles/s41591-024-02...

    ..."No serious adverse events were reported that were related to either ARCEX Therapy or study procedures in any of the 64 participants who were exposed to any procedures of the Up-LIFT trial (Table 3). A total of 238 adverse events occurred throughout the duration of the study (Table 3, Extended Data Table 3 and Supplementary Data 2). These adverse events were reported in 50 of the 64 individuals who were exposed to any aspect of the Up-LIFT trial procedures. Three of these 238 adverse events were considered serious due to hospitalization associated with the event yet were unrelated to ARCEX Therapy or study procedures. They included constipation, urinary tract infections and bladder stone. Forty-four non-serious adverse events were related to ARCEX Therapy and were reported in 17 of the 64 participants (Table 3). One of these 44 events was a severe adverse event, which was reported in one participant and was related to the occurrence of severe muscle spasms during one rehabilitation session within the ARCEX Therapy period, but it was unrelated to ARCEX Therapy because the stimulation was not turned on when these spasms occurred. There were no unexpected adverse events"...

    Je zou wellicht iets van hartritmestoornissen verwachten, door die pulsjes;
    maar dat is - vooralsnog - niet zo. Nu gaat dus een aantal revalidatieklinie-
    ken in de VS met ARC-EX aan de slag.
    Ik denk dat wanneer de studieresultaten over 'n periode van 'n maand of 6
    worden bevestigd, de goedkeuring voor thuisgebruik slechts 'n formaliteit
    zal zijn.
  2. Jabu5824 2 januari 2025 10:54
    Gelezen, mooi stuk, positieve resultaten.

    ..."No serious adverse events were reported that were related to either ARCEX Therapy or study procedures in any of the 64 participants who were exposed to any procedures of the Up-LIFT trial (Table 3). A total of 238 adverse events occurred throughout the duration of the study (Table 3, Extended Data Table 3 and Supplementary Data 2). These adverse events were reported in 50 of the 64 individuals who were exposed to any aspect of the Up-LIFT trial procedures. Three of these 238 adverse events were considered serious due to hospitalization associated with the event yet were unrelated to ARCEX Therapy or study procedures. They included constipation, urinary tract infections and bladder stone. Forty-four non-serious adverse events were related to ARCEX Therapy and were reported in 17 of the 64 participants (Table 3). One of these 44 events was a severe adverse event, which was reported in one participant and was related to the occurrence of severe muscle spasms during one rehabilitation session within the ARCEX Therapy period, but it was unrelated to ARCEX Therapy because the stimulation was not turned on when these spasms occurred. There were no unexpected adverse events"...

    Je zou wellicht iets van hartritmestoornissen verwachten, door die pulsjes;
    maar dat is - vooralsnog - niet zo. Nu gaat dus een aantal revalidatieklinie-
    ken in de VS met ARC-EX aan de slag.
    Ik denk dat wanneer de studieresultaten over 'n periode van 'n maand of 6
    worden bevestigd, de goedkeuring voor thuisgebruik slechts 'n formaliteit
    zal zijn.
    [/quote]
  3. forum rang 4 nb 2 januari 2025 11:30
    quote:

    Ponzi_NL schreef op 2 januari 2025 11:04:

    dit kan qua populariteit de nieuwe Galapagos worden
    Krijg je al een st.jv.? Holy Mozes
  4. Ponzi_NL 2 januari 2025 15:17
    Recente analistenrapporten tonen optimisme over ONWARD Medical. KBC Securities heeft op 20 december 2024 het koersdoel verhoogd van €8,70 naar €10,40, met een verwacht rendement van +123,18% en een herhaald koopadvies.

    Daarnaast heeft Degroof Petercam op 23 december 2024 het koersdoel verhoogd van €14,10 naar €16,20, met een verwacht rendement van +247,64% en eveneens een koopadvies.
  5. forum rang 6 Kaviaar 2 januari 2025 16:50
    En dan binnenkort een bericht van overname?
    Het gemiddelde van afgelopen beursdagen (waarbij de koers min of meer gedrukt werd en wordt)…

    Maar, geen zorgen. AFM kijkt mee (met hun ogen dicht, dat wel).
1.513 Posts
Pagina: 1 2 3 4 5 6 ... 76 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursonline.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.345
AB InBev 2 5.576
Abionyx Pharma 2 29
Ablynx 43 13.357
ABN AMRO 1.582 53.386
ABO-Group 1 27
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 11.740
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 197
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 18.075
Aedifica 3 1.003
Aegon 3.258 323.711
AFC Ajax 538 7.116
Affimed NV 2 6.356
ageas 5.844 109.952
Agfa-Gevaert 14 2.098
Ahold 3.540 74.443
Air France - KLM 1.025 35.714
AIRBUS 1 13
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.123
Alfen 17 27.353
Allfunds Group 4 1.617
Almunda Professionals (vh Novisource) 651 4.255
Alpha Pro Tech 1 17
Alphabet Inc. 1 445
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.487 114.835
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.846 246.256
AMG 972 136.201
AMS 3 73
Amsterdam Commodities 305 6.810
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 514
Antonov 22.632 153.605
Aperam 92 15.291
Apollo Alternative Assets 1 17
Apple 5 405
Arcadis 252 9.023
Arcelor Mittal 2.038 321.652
Archos 1 1
Arcona Property Fund 1 303
arGEN-X 17 10.734
Aroundtown SA 1 227
Arrowhead Research 5 9.791
Ascencio 1 35
ASIT biotech 2 697
ASMI 4.108 39.990
ASML 1.767 118.659
ASR Nederland 21 4.550
ATAI Life Sciences 1 7
Atenor Group 1 548
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 33 15.730
Axsome Therapeutics 1 177
Azelis Group 1 86
Azerion 7 3.644